Table 4 Factors obtained from a cox model and associated with observed mortality for adenocarcinomas, squamous cell cancers and small cell cancers diagnosed in 2004 and recruited among 10 French cancer registries
Adenocarcinomas (n = 646) | Squamous cell cancers (n = 524) | Small cell cancers (n = 233) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Time (years)a | Unadjusted Hazard Ratios | Time (years) a | Adjusted Hazard Ratios | Time (years) a | Unadjusted Hazard Ratios | Time (years) a | Adjusted Hazard Ratios | Time (years) a | Unadjusted Hazard Ratios | Time (years) a | Adjusted Hazard Ratios | |
Sex | ||||||||||||
Male | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
Female | 0–8 | 0.8 (0.6–0.9) | 0–8 | 0.7 (0.6–0.8) | 0–8 | 1.1 (0.8–1.6) | 0–8 | 1.3 (1.0–1.8) | 0–8 | 0.8 (0.6–1.1) | 0–8 | 0.7 (0.5–1.0) |
Age group | ||||||||||||
< 50 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
50–59 | 0–8 | 1.1 (0.9–1.5) | 0–8 | 1.0 (0.7–1.3) | 0–8 | 1.0 (0.6–1.6) | 0–8 | 0.9 (0.6–1.5) | 0–8 | 1.0 (0.6–1.8) | 0–8 | 0.9 (0.5–1.6) |
60–69 | 0–8 | 1.3 (1.0–1.7) | 0–8 | 1.1 (0.8–1.4) | 0–8 | 0.9 (0.5–1.4) | 0–8 | 0.9 (0.5–1.5) | 0–8 | 1.4 (0.8–2.4) | 0–8 | 1.0 (0.6–1.7) |
70–79 | 0–8 | 1.2 (0.9–1.6) | 0–8 | 1.2 (0.9–1.6) | 0–8 | 1.1 (0.7–1.8) | 0–8 | 1.4 (0.8–2.3) | 0–8 | 1.9 (1.1–3.2) | 0–8 | 1.3 (0.8–2.3) |
≥ 80 | 0–8 | 2.2 (1.5–3.2) | 0–8 | 2.9 (2.0–4.3) | 0–8 | 1.9 (1.1–3.2) | 0–8 | 1.9 (1.1–3.2) | 0–8 | 3.1 (1.6–6.1) | 0–8 | 2.5 (1.3–4.9) |
Charlson Comorbidity Index | ||||||||||||
0 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
1 | 0–8 | 1.0 (0.8–1.2) | 0–8 | 1.0 (0.8–1.3) | 0–8 | 1.0 (0.8–1.3) | 0–8 | 1.0 (0.8–1.3) | 0–8 | 1.3 (0.9–1.8) | 0–8 | 1.6 (1.1–2.3) |
2 | 0–8 | 0.9 (0.7–1.2) | 0–8 | 0.8 (0.6–1.1) | 0–8 | 0.9 (0.7–1.2) | 0–8 | 0.9 (0.6–1.2) | 0–8 | 1.4 (0.9–2.1) | 0–8 | 1.7 (1.1–2.7) |
≥ 3 | 0–8 | 1.3 (1.0–1.7) | 0–8 | 1.2 (0.9–1.6) | 0–8 | 1.1 (0.8–1.4) | 0–8 | 0.9 (0.6–1.2) | 0–8 | 2.4 (1.5–3.7) | 0–8 | 2.7 (1.7–4.4) |
Unknown | 0–8 | 2.1 (1.4–3.3) | 0–8 | 1.6 (1.0–2.6) | 0–8 | 1.1 (0.7–1.9) | 0–8 | 0.9 (0.6–1.6) | 0–8 | 1.4 (0.7–2.8) | 0–8 | 1.2 (0.6–2.5) |
Stage (non-small cell cancers) | ||||||||||||
1 | 1 | 1 | 1 | 1 | – | – | ||||||
2 | 0–8 | 1.1 (0.6–2.2) | 0–1 | 0.4 (0.1–3.3) | 0–8 | 1.1 (0.7–1.7) | 0–8 | 1.1 (0.7–1.8) | – | – | ||
1–8 | 1.3 (0.0–90.3) | |||||||||||
3 | 0–8 | 3.2 (2.2–4.5) | 0–1 | 3.3 (1.6–6.7) | 0–8 | 2.6 (1.8–3.7) | 0–8 | 2.8 (2.0–4.0) | – | – | ||
1–8 | 3.3 (0.7–15.3) | |||||||||||
4 | 0–8 | 6.9 (5.0–9.6) | 0–1 | 8.7 (4.4–17.1) | 0–8 | 6.1 (4.3–8.7) | 0–8 | 6.7 (4.6–9.6) | – | – | ||
1–8 | 6.4 (1.5–27.5) | |||||||||||
Unknown | 0–8 | 5.6 (3.0–10.5) | 0–1 | 8.2 (3.2–21.0) | 0–8 | 7.0 (4.3–11.4) | 0–8 | 7.2 (4.4–11.7) | – | – | ||
1–8 | 3.2 (0.3–33.2) | |||||||||||
Stage (small cell cancers) | ||||||||||||
Limited | – | – | – | – | 1 | 1 | ||||||
Extensive | – | – | – | – | 0–8 | 2.7 (1.9–3.6) | 0–8 | 3.1 (2.2–4.4) | ||||
Unknown | – | – | – | – | 0–8 | 6.2 (3.1–12.5) | 0–8 | 4.7 (2.1–10.2) | ||||
Diagnostic mode | ||||||||||||
Pulmonary symptoms | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
Incidental diagnosis | 0–1 | 0.8 (0.6–1.0) | 0–1 | 0.7 (0.5–1.1) | 0–8 | 0.9 (0.7–1.3) | 0–8 | 0.9 (0.7–1.2) | 0–8 | 0.7 (0.4–1.1) | 0–8 | 0.8 (0.4–1.3) |
1–8 | 0.7 (0.4–1.3) | 1–8 | 1.0 (0.4–2.5) | |||||||||
Non-pulmonary symptoms | 0–1 | 1.3 (1.1–1.6) | 0–1 | 1.1 (0.8–1.4) | 0–8 | 1.8 (1.4–2.3) | 0–8 | 1.5 (1.2–1.9) | 0–8 | 1.2 (0.9–1.7) | 0–8 | 1.1 (0.8–1.5) |
1–8 | 1.6 (0.9–2.6) | 1–8 | 0.9 (0.5–1.7) | |||||||||
Surveillance of high-risk patients | 0–1 | 0.5 (0.3–0.7) | 0–1 | 0.4 (0.2–1.1) | 0–8 | 1.0 (0.6–1.8) | 0–8 | 1.1 (0.6–2.0) | 0–8 | 1.0 (0.2–4.1) | 0–8 | 2.0 (0.5–8.7) |
1–8 | 0.3 (0.1–0.8) | 1–8 | 1.2 (0.1–10.4) | |||||||||
Unknown | 0–1 | 1.4 (0.8–2.5) | 0–1 | 1.0 (0.5–2.4) | 0–8 | 1.3 (0.6–2.5) | 0–8 | 1.6 (0.8–3.2) | 0–8 | 2.3 (1.0–5.3) | 0–8 | 1.6 (0.6–4.3) |
1–8 | 3.4 (0.8–13.7) | 1–8 | 1.9 (0.3–14.2) | |||||||||